The Anti-Inflammatory Therapeutics Market is segmented by Application (RA, Psoriasis, and MS), Drug Class (Anti-inflammatory biologicals, Corticosteroids, and NSAIDs), and Geography (North America, Europe, Asia, and Rest of World (ROW)). As per the Global Forecast research report 2024-2028 published by Technavio, the market size is estimated to grow by USD 38.7 billion, at a CAGR of 6.3% during the forecast period. There are several companies that are contributing to the market as per this report. Emergence of novel anti-inflammatory drugs .
In the realm of health and wellness, rheumatoid arthritis (RA) is a significant autoimmune disease, characterized by joint pain and inflammation. This condition arises when the immune system mistakenly attacks healthy cells within the body, leading to inflammation in the affected areas. The etiology of RA remains elusive, although various risk factors have been identified. As per the Centers for Disease Control and Prevention (CDC), approximately 54.4 million US adults grapple with arthritis, equating to 25% of the population. Arthritis is a leading cause of disability, manifesting as joint aching, pain, stiffness, and swelling. The economic and societal burden of this debilitating condition necessitates the development of effective anti-inflammatory therapeutics.
For insights on company offerings- Request a sample report!
The Anti-Inflammatory Therapeutics Market represents a significant business opportunity due to the rising prevalence of chronic inflammatory diseases. Key players in this market are focusing on developing innovative solutions to address unmet medical needs, leveraging advanced technologies and research. The market is expected to grow steadily, driven by increasing demand for effective anti-inflammatory therapies and expanding healthcare expenditures. Companies are investing in R&D to bring novel products to market, ensuring long-term growth prospects.
To access the valuable insights - Download the Free Sample Report
The Anti-Inflammatory Therapeutics market has gained significant attention in recent times due to the increasing incidence of acute respiratory distress, pneumonia, and other respiratory diseases caused by beta coronavirus, which can lead to a cytokine storm. These conditions are characterized by inflammation, swelling, and pain, which call for effective anti-inflammatory therapeutics. Anti-inflammatory therapeutics, including Remicade, have been widely used for the treatment of various inflammatory conditions such as rheumatoid arthritis, menstrual pain, sprains, chronic pain, infectious illnesses, and autoimmune diseases. However, the negative effects of these therapeutics, including headaches, migraines, and increased prostaglandin levels, have led to the exploration of alternative treatments. Pharmaceuticals are developing biosimilars and anti-inflammatory biologics to mitigate the negative effects and patent expiration of conventional anti-inflammatory medications. The global anti-inflammatory therapeutics market is expected to grow significantly due to the increasing prevalence of respiratory diseases, autoimmune diseases, and chronic illnesses. The market is also driven by the rising demand for effective pain relief and inflammation reduction in various conditions.
The global pharmaceuticals market, encompassing entities involved in the research and development (R&D) or manufacturing of generic and non-generic drugs, as well as veterinary drugs, represents a significant sector within the larger healthcare industry. According to Technavio's market analysis, the healthcare market size is determined by the consolidated revenue generated by providers of equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services. Key growth drivers for the pharmaceuticals market include the increasing global population aging, with the number of individuals over 60 years old in the US projected to reach approximately 25% by 2050, and Europe projected to reach a similar demographic ratio by 2030. - The Anti-Inflammatory Therapeutics Market is experiencing significant growth, fueled by the . Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
Safe and Secure SSL Encrypted
One user only.
Quick & easy download option
Unlimited user access (Within your organization).
Complimentary Customization Included
*For Enterprise license, go to checkout page
Get the report (PDF) sent to your email within minutes.
